Clinical efficacy of Dapagliflozin for patients with type 2 diabetes and coronary heart disease and its effect on the coagulation function of the patients
XIN Li
Departmentof Cardiology, Anshan Central Hospital, Liaoning Province, Anshan 114000, China
Abstract:Objective To explore the clinical efficacy of Dapagliflozin for patients with type 2 diabetes and coronary heart disease (T2DM/CHD) and its effect on the coagulation function of the patients. Methods A total of 86 T2DM/CHD patients admitted to Anshan Central Hospital from June 2019 to March 2021 were selected as the subjects, and they were divided into control group and observation group according to random number table method, with 43 cases in each group. The control group was given Metformin Hydrochloride, and the observation group was given Dapagliflozin on the basis of the control group. Both groups were treated for 3 consecutive months. The fasting blood glucose (FPG),glycosylated hemoglobin (HbA1c), triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol (LDL-C), thrombin time (TT), activated partial thromboplastin time(APTT), D-dimer (D-D), fibrinogen (FIB) were compare between the two groups. Results There were no significant differences in FPG, HbA1c, TG, TC, HDL-C, LDL-C, TT, APTT, D-D and FIB between the two groups before treatment(P>0.05). After treatment, FPG, HbA1c, FINS, TG, TC, LDL-C, D-D and FIB in the two groups were lower than those before treatment, the differences were statistically significant (P<0.05). After treatment, HDL-C levels in the two groups were higher than those before treatment, the differences were statistically significant (P<0.05). After treatment, TT and APTT in the two groups were longer than those before treatment, the differences were statistically significant (P<0.05).After treatment, FPG, HbA1c, FINS, TG, TC, LDL-C, D-D and FIB in observation group were lower than those in control group, the differences were statistically significant (P<0.05). After treatment, the HDL-C of observation group was higher than that of control group, the difference was statistically significant (P<0.05). After treatment, TT and APTT of observation group were longer than those in the control group, the differences were statistically significant (P<0.05).Conclusions Dapagliflozin is effective in treating patients with the T2DM/CHD, and has obvious advantages in improving blood glucose, blood lipids, and the body's hypercoagulable state.
辛 丽. 达格列净治疗2型糖尿病并冠心病患者的临床效果及对患者凝血功能的影响[J]. 中国当代医药, 2022, 29(4): 93-96.
XIN Li. Clinical efficacy of Dapagliflozin for patients with type 2 diabetes and coronary heart disease and its effect on the coagulation function of the patients. 中国当代医药, 2022, 29(4): 93-96.
Artime E,Romera I,Díaz-Cerezo S,et al.Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain:A Systematic Review[J].Diabetes Ther,2021,12(6):1631-1659.
Dharmalingam M,Aravind SR,Thacker H,et al.Efficacy and Safety of Remogliflozin Etabonate,a New Sodium Glucose Co-Transporter-2 Inhibitor,in Patients with Type 2 Diabetes Mellitus:A 24-Week,Randomized,Double-Blind,Active-Controlled Trial[J].Drugs,2020,80(6):587-600.
[9]
Liu Z,Ma X,Ilyas I,et al.Impact of sodium glucose cotransporter 2(SGLT2)inhibitors on atherosclerosis:from pharmacology to pre-clinical and clinical therapeutics[J].Theranostics,2021,11(9):4502-4515.